Preoperative profiling of symptomatic breast cancer by diagnostic core biopsy

Annals of Surgical Oncology

Volumn 13, Issue 1, 2006, Pages 45-51

  Cahill, Ronan A ^a   Walsh, Daniel ^a   Landers, Rob J ^a   Watson, R Gordon ^a  

^a WATERFORD REGIONAL HOSPITAL   (Ireland)

Author keywords

Breast cancer; Core biopsy; Preoperative; Profile

Indexed keywords

EOSIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HEMATOXYLIN; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PREOPERATIVE EVALUATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SCORING SYSTEM; TREATMENT PLANNING; TUMOR BIOPSY;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM STAGING; PREOPERATIVE CARE; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 30944468134     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/ASO.2006.03.047     Document Type: Article

References (42)

1. Cross SS. Grading and scoring in histopathology. Histopathology 1998; 33:99-106.
2. Cross SS. Kappa statistics as indicators of quality assurance in histopathology and cytopathology. J Clin Pathol 1996; 49:597-9.
3. Silcocks PB. Measuring repeatability and validity of histological diagnosis - a brief review with some practical examples. J Clin Pathol 1983; 36:1269-75.
4. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33:159-74.
5. Kaufmann M, von Minckwitz G, Smith R, et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol 2003; 21:2600-8.
6. Mano MS, Awada AS. Primary chemotherapy for breast cancer: the evidence and the future. Ann Oncol 2004; 15:1161-71.
7. Piper GL, Patel NA, Patel JA, Malay MB, Julian TB. Neoadjuvant chemotherapy for locally advanced breast cancer results in alterations in preoperative tumor marker status. Am Surg 2004; 70:1103-6.
8. Bosch AM, Kessels AG, Beets GL, et al. Preoperative examination of the pathological breast tumour size by physical examination, mammography and ultrasound: a prospective study on 105 invasive tumours. Eur J Radiol 2003; 48:285-92.
9. Snelling JD, Abdullah N, Brown G, King DM, Moskovic E, Gui GP. Measurement of tumour size in case selection for breast cancer therapy by clinical assessment and ultrasound. Eur J Surg Oncol 2004; 30:5-9.
10. Podkrajsek M, Music MM, Kadivec M, et al. Role of ultrasound in the preoperative staging of patients with breast cancer. Eur Radiol 2005; 15:1044-50.
11. Zgajnar J, Frkovic-Grazio S, Besic N, et al. Low sensitivity of the touch imprint cytology of the sentinel lymph node in breast cancer patients - results of a large series. J Surg Oncol 2004; 85:82-6.
12. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351:2817-26.
13. Yu K, Lee C, Tan PH, et al. A molecular signature of the Nottingham prognostic index in breast cancer. Cancer Res 2004; 64:2962-8.
14. Denley H, Pinder SE, Elston CW, Lee AH, Ellis IO. Preoperative assessment of prognostic factors in breast cancer. J Clin Pathol 2001; 54:20-4.
15. Sharifi S, Peterson MK, Baum JK, Raza S, Schnitt SJ. Assessment of pathologic prognostic factors in breast core needle biopsies. Mod Pathol 1999; 12:941-5.
16. Shannon J, Douglas-Jones AG, Dallimore NS. Conversion to core biopsy in preoperative diagnosis of breast lesions. Is it justified by the results? J Clin Pathol 2001; 54:762-5.
17. Cross SS. Correspondence re: Sharifi S, Peterson MK, Baum JK, Raza S, Schnitt SJ. Assessment of pathologic prognostic factors in breast core needle biopsies. Mod Pathol 1999;12:941-945. Mod Pathol 1999;12:1332.
18. Sinha PS, Bendall S, Bates T. Does routine grading of invasive lobular cancer of the breast have the same prognostic significance as for ductal cancers? Eur J Surg Oncol 2000; 26:733-7.
19. Moore MM, Borossa G, Imbrie JZ, et al. Association of infiltrating lobular carcinoma with positive surgical margins after breast-conserving therapy. Ann Surg 2000; 231:877-82.
20. Schnitt SJ, Jacobs TW. Current status of Her-2 testing: caught between a rock and a hard place. Am J Clin Pathol 2001; 116:806-10.
21. Ring AE, Smith IE, Ashley S, Fulford LG, Lakhani SR. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer 2004; 91:2012-7.
22. Rubin MA, Gage WR, Fedor HH, De Marzo AM. Inadequate formalin fixation decreases reliability of p27 immunohistochemical staining: probing optimal fixation time using high-density tissue microarrays. Hum Pathol 2002; 33:756-60.
23. Lee SH, Chung MA, Quddus MR, Steinhoff MM, Cady B. The effect of neoadjuvant chemotherapy on oestrogen and progesterone receptor expression and hormone receptor status in breast cancer. Am J Surg 2003; 186:348-50.
24. Ross JS, Fletcher JA, Linette GP, et al. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 2003; 8:307-25.
25. Eccles SA. The role of c-erbB-2/Her2/neu in breast cancer progression and metastases. J Mammary Gland Biol Neoplasia 2001; 6:393-406.
26. Yarden Y. Biology of Her2 and its importance in breast cancer. Oncology 2001; 61(Suppl 2):1-13.
27. Piccart M, Lohrisch C, DiLeo A, Larsimont D. The predictive value of Her-2 in breast cancer. Oncology 2001; 61(Suppl 2):73-82.
28. Konecny G, Pauletti G, Pegram M, et al. Quantitative association between Her-2/neu and steroid hormone receptors in hormone-receptor positive primary breast cancer. J Natl Cancer Inst 2003; 95:142-53.
29. Dowsett M. Overexpression of Her-2 as a resistance mechanism to hormonal therapy for breast cancer. Endocr Relat Cancer 2001; 8:191-5.
30. Carlomagno C, Perrone F, Gallo C, et al. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without ancillary lymph node metastases. J Clin Oncol 1996; 14:2702-8.
31. Schmid P, Wischnewsky MB, Sezer O, Bohm R, Possinger K. Prediction of response to hormonal treatment in metastatic breast cancer. Oncology 2002; 63:309-16.
32. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1 and/or ErbB-2 positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomised trial. J Clin Oncol 2001; 19:3808-16.
33. Muss HB, Thor AD, Berry DA, et al. c-erb-B2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994; 330:1260-6.
34. Baselga J, Seidman AD, Rosen PP, Norton L. Her2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implication. Oncology 1997; 11(Suppl 2):43-8.
35. Ligibel JA, Winer EP. Trastuzumab/chemotherapy combinations in metastatic breast cancer. Semin Oncol 2002; 29(Suppl 11):38-43.
36. Hortobagyi GN. Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer. Semin Oncol 2001; 28(Suppl 18):43-7.
37. McKeage K, Perry CM. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing Her-2. Drugs 2002; 62:209-43.
38. Engel J, Eckel R, Kerr J, et al. The process of metastasisation for breast cancer. Eur J Cancer 2003; 39:1794-806.
39. Collett K, Skjaerven R, Maehle BO. The prognostic contribution of estrogen and progesterone receptor status to a modified version of the Nottingham Prognostic Index. Breast Cancer Res Treat 1998; 48:1-9.
40. Cooke T, Reeves J, Lannigan A, Stanton P. The value of human epidermal growth factor receptor-2 (HER2) as a prognostic marker. Eur J Cancer 2001; 37(Suppl 1):3-10.
41. D'Eredita G, Giardina C, Martellotta M, Natale T, Ferrarese F. Prognostic factors in breast cancer: the predictive value of the Nottingham Prognostic Index in patients with a long-term follow-up that were treated in a single institution. Eur J Cancer 2001; 37:591-6.
42. Emens LA, Davidson NE. The follow-up of breast cancer. Semin Oncol 2003; 30:338-48.